Rebound in travel helps vaccine maker Valneva post smaller-than-expected loss

Published by
Reuters UK

(Reuters) – French vaccine maker Valneva reported on Thursday a smaller-than-expected first-quarter loss as sales of travel vaccines Dukoral and Ixiaro improved, propelling its shares 16% up. Valneva also confirmed its sales outlook for 2023, with revenue expected between 220 million euros and 260 million euros. “We managed to double our first-quarter vaccine sales year-over-year, keeping us on track to deliver on our full-year sales guidance,” Chief Financical Officer Peter Bühler said in a results statement. After the European Commission dropped nearly all of its orders of 60 million doses o…

Read More

See also  Russell Westbrook credits improved hand health for his recent surge

Leave a Reply